Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Possible pulsed gamma ray emission above 50 MeV from the Crab pulsar.

Nature

Vasseur J, Paul J, Parlier B, Leray JP, Forichon M, Agrinier B, Boella G, Maraschi L, Treves A, Buccheri R, Scarsi L.
PMID: 16057374
Nature. 1970 May 09;226(5245):534-5. doi: 10.1038/226534a0.

No abstract available.

Cite
Vasseur J, Paul J, Parlier B, et al. Possible pulsed gamma ray emission above 50 MeV from the Crab pulsar. Nature. 1970;226(5245):534-5doi: 10.1038/226534a0.
Vasseur, J., Paul, J., Parlier, B., Leray, J. P., Forichon, M., Agrinier, B., Boella, G., Maraschi, L., Treves, A., Buccheri, R., & Scarsi, L. (1970). Possible pulsed gamma ray emission above 50 MeV from the Crab pulsar. Nature, 226(5245), 534-5. https://doi.org/10.1038/226534a0
Vasseur, J, et al. "Possible pulsed gamma ray emission above 50 MeV from the Crab pulsar." Nature vol. 226,5245 (1970): 534-5. doi: https://doi.org/10.1038/226534a0
Vasseur J, Paul J, Parlier B, Leray JP, Forichon M, Agrinier B, Boella G, Maraschi L, Treves A, Buccheri R, Scarsi L. Possible pulsed gamma ray emission above 50 MeV from the Crab pulsar. Nature. 1970 May 09;226(5245):534-5. doi: 10.1038/226534a0. PMID: 16057374.
Copy Download .nbib Format: NLM
In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.

HIV medicine

Roberts O, Kinvig H, Owen A, Lamorde M, Siccardi M, Scarsi KK.
PMID: 34328253
HIV Med. 2021 Nov;22(10):898-906. doi: 10.1111/hiv.13136. Epub 2021 Jul 30.

OBJECTIVES: The World Health Organization recommends that all countries adopt dolutegravir-based antiretroviral therapy as the preferred regimen for all individuals living with HIV. Levonorgestrel is a commonly used hormonal contraceptive, which undergoes drug-drug interactions with some antiretrovirals, but the...

Cite
Roberts O, Kinvig H, Owen A, et al. In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV Med. 2021;22(10):898-906doi: 10.1111/hiv.13136.
Roberts, O., Kinvig, H., Owen, A., Lamorde, M., Siccardi, M., & Scarsi, K. K. (2021). In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV medicine, 22(10), 898-906. https://doi.org/10.1111/hiv.13136
Roberts, Owain, et al. "In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel." HIV medicine vol. 22,10 (2021): 898-906. doi: https://doi.org/10.1111/hiv.13136
Roberts O, Kinvig H, Owen A, Lamorde M, Siccardi M, Scarsi KK. In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV Med. 2021 Nov;22(10):898-906. doi: 10.1111/hiv.13136. Epub 2021 Jul 30. PMID: 34328253.
Copy Download .nbib Format: NLM
An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia.

Muscle & nerve

Gemelli C, Traverso M, Trevisan L, Fabbri S, Scarsi E, Carlini B, Prada V, Mongini T, Ruggiero L, Patrone S, Gallone S, Iodice R, Pisciotta L, Zara F, Origone P, Rota E, Minetti C, Bruno C, Schenone A, Mandich P, Fiorillo C, Grandis M.
PMID: 34687219
Muscle Nerve. 2022 Jan;65(1):96-104. doi: 10.1002/mus.27448. Epub 2021 Nov 08.

INTRODUCTION/AIMS: Currently, there are no straightforward guidelines for the clinical and diagnostic management of hyperCKemia, a frequent and nonspecific presentation in muscle diseases. Therefore, we aimed to describe our diagnostic workflow for evaluating patients with this condition.METHODS: We selected...

Cite
Gemelli C, Traverso M, Trevisan L, et al. An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia. Muscle Nerve. 2021;65(1):96-104doi: 10.1002/mus.27448.
Gemelli, C., Traverso, M., Trevisan, L., Fabbri, S., Scarsi, E., Carlini, B., Prada, V., Mongini, T., Ruggiero, L., Patrone, S., Gallone, S., Iodice, R., Pisciotta, L., Zara, F., Origone, P., Rota, E., Minetti, C., Bruno, C., Schenone, A., Mandich, P., Fiorillo, C., & Grandis, M. (2022). An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia. Muscle & nerve, 65(1), 96-104. https://doi.org/10.1002/mus.27448
Gemelli, Chiara, et al. "An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia." Muscle & nerve vol. 65,1 (2022): 96-104. doi: https://doi.org/10.1002/mus.27448
Gemelli C, Traverso M, Trevisan L, Fabbri S, Scarsi E, Carlini B, Prada V, Mongini T, Ruggiero L, Patrone S, Gallone S, Iodice R, Pisciotta L, Zara F, Origone P, Rota E, Minetti C, Bruno C, Schenone A, Mandich P, Fiorillo C, Grandis M. An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia. Muscle Nerve. 2022 Jan;65(1):96-104. doi: 10.1002/mus.27448. Epub 2021 Nov 08. PMID: 34687219.
Copy Download .nbib Format: NLM
Deadly Puppy Infection Caused by an MDR .

Frontiers in microbiology

Mattioni Marchetti V, Bitar I, Mercato A, Nucleo E, Marchesini F, Mancinelli M, Prati P, Scarsi GS, Hrabak J, Pagani L, Fabbi M, Migliavacca R.
PMID: 32351465
Front Microbiol. 2020 Apr 15;11:584. doi: 10.3389/fmicb.2020.00584. eCollection 2020.

Antimicrobial consumption in veterinary medicine has led to the spread of multi drug-resistance in clinically important bacteria, with the companion animals and their environment involved as emerging reservoirs. While CTX-M-15 and CMY-2 acquired β-lactamases have been widely detected in...

Cite
Mattioni Marchetti V, Bitar I, Mercato A, et al. Deadly Puppy Infection Caused by an MDR . Front Microbiol. 2020;11:584doi: 10.3389/fmicb.2020.00584.
Mattioni Marchetti, V., Bitar, I., Mercato, A., Nucleo, E., Marchesini, F., Mancinelli, M., Prati, P., Scarsi, G. S., Hrabak, J., Pagani, L., Fabbi, M., & Migliavacca, R. (2020). Deadly Puppy Infection Caused by an MDR . Frontiers in microbiology, 11584. https://doi.org/10.3389/fmicb.2020.00584
Mattioni Marchetti, Vittoria, et al. "Deadly Puppy Infection Caused by an MDR ." Frontiers in microbiology vol. 11 (2020): 584. doi: https://doi.org/10.3389/fmicb.2020.00584
Mattioni Marchetti V, Bitar I, Mercato A, Nucleo E, Marchesini F, Mancinelli M, Prati P, Scarsi GS, Hrabak J, Pagani L, Fabbi M, Migliavacca R. Deadly Puppy Infection Caused by an MDR . Front Microbiol. 2020 Apr 15;11:584. doi: 10.3389/fmicb.2020.00584. eCollection 2020. PMID: 32351465; PMCID: PMC7174561.
Copy Download .nbib Format: NLM
Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States.

Open forum infectious diseases

Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH.
PMID: 31412131
Open Forum Infect Dis. 2019 Oct 01;6(10). doi: 10.1093/ofid/ofz365.

BACKGROUND: HIV pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition, yet significant barriers exist to its prescription and use. Incorporating pharmacists in the PrEP care process may help increase access to PrEP services.METHODS: Our pharmacist-led PrEP program...

Cite
Havens JP, Scarsi KK, Sayles H, et al. Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States. Open Forum Infect Dis. 2019;6(10)doi: 10.1093/ofid/ofz365.
Havens, J. P., Scarsi, K. K., Sayles, H., Klepser, D. G., Swindells, S., & Bares, S. H. (2019). Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States. Open forum infectious diseases, 6(10), . https://doi.org/10.1093/ofid/ofz365
Havens, Joshua P, et al. "Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States." Open forum infectious diseases vol. 6,10 (2019). doi: https://doi.org/10.1093/ofid/ofz365
Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH. Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States. Open Forum Infect Dis. 2019 Oct 01;6(10). doi: 10.1093/ofid/ofz365. PMID: 31412131; PMCID: PMC6765348.
Copy Download .nbib Format: NLM
Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada.

Annals of the rheumatic diseases

Piantoni S, Andreoli L, Colombo E, Mendeni M, Ghirardelli ML, Brucato A, Imazio M, Furloni R, Franceschini F, Airó P, Scarsi M.
PMID: 33504480
Ann Rheum Dis. 2021 Jan 27; doi: 10.1136/annrheumdis-2020-219787. Epub 2021 Jan 27.

No abstract available.

Cite
Piantoni S, Andreoli L, Colombo E, et al. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219787.
Piantoni, S., Andreoli, L., Colombo, E., Mendeni, M., Ghirardelli, M. L., Brucato, A., Imazio, M., Furloni, R., Franceschini, F., Airó, P., & Scarsi, M. (2021). Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219787
Piantoni, Silvia, et al. "Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219787
Piantoni S, Andreoli L, Colombo E, Mendeni M, Ghirardelli ML, Brucato A, Imazio M, Furloni R, Franceschini F, Airó P, Scarsi M. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada. Ann Rheum Dis. 2021 Jan 27; doi: 10.1136/annrheumdis-2020-219787. Epub 2021 Jan 27. PMID: 33504480.
Copy Download .nbib Format: NLM
Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.

AIDS research and treatment

Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT.
PMID: 22500218
AIDS Res Treat. 2012;2012:703604. doi: 10.1155/2012/703604. Epub 2012 Mar 05.

Background. Nevirapine- (NVP-) based antiretroviral therapy (ART) and artesunate-amodiaquine are frequently coprescribed in areas of HIV and malaria endemicity. We explored the impact of this practice on artesunate and dihydroartemisinin pharmacokinetics. Methods. We conducted a parallel-group pharmacokinetic comparison between...

Cite
Fehintola FA, Scarsi KK, Ma Q, et al. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012;2012:703604doi: 10.1155/2012/703604.
Fehintola, F. A., Scarsi, K. K., Ma, Q., Parikh, S., Morse, G. D., Taiwo, B., Akinola, I. T., Adewole, I. F., Lindegardh, N., Phakderaj, A., Ojengbede, O., Murphy, R. L., Akinyinka, O. O., & Aweeka, F. T. (2012). Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS research and treatment, 2012703604. https://doi.org/10.1155/2012/703604
Fehintola, Fatai A, et al. "Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults." AIDS research and treatment vol. 2012 (2012): 703604. doi: https://doi.org/10.1155/2012/703604
Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012;2012:703604. doi: 10.1155/2012/703604. Epub 2012 Mar 05. PMID: 22500218; PMCID: PMC3303559.
Copy Download .nbib Format: NLM
Response to Dong et al.

Open forum infectious diseases

Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH.
PMID: 32099845
Open Forum Infect Dis. 2020 Jan 27;7(2):ofaa032. doi: 10.1093/ofid/ofaa032. eCollection 2020 Feb.

No abstract available.

Cite
Havens JP, Scarsi KK, Sayles H, et al. Response to Dong et al. Open Forum Infect Dis. 2020;7(2):ofaa032doi: 10.1093/ofid/ofaa032.
Havens, J. P., Scarsi, K. K., Sayles, H., Klepser, D. G., Swindells, S., & Bares, S. H. (2020). Response to Dong et al. Open forum infectious diseases, 7(2), ofaa032. https://doi.org/10.1093/ofid/ofaa032
Havens, Joshua P, et al. "Response to Dong et al." Open forum infectious diseases vol. 7,2 (2020): ofaa032. doi: https://doi.org/10.1093/ofid/ofaa032
Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH. Response to Dong et al. Open Forum Infect Dis. 2020 Jan 27;7(2):ofaa032. doi: 10.1093/ofid/ofaa032. eCollection 2020 Feb. PMID: 32099845; PMCID: PMC7031060.
Copy Download .nbib Format: NLM
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.

Current opinion in HIV and AIDS

Bares SH, Scarsi KK.
PMID: 34871188
Curr Opin HIV AIDS. 2022 Jan 01;17(1):22-31. doi: 10.1097/COH.0000000000000708.

PURPOSE OF REVIEW: Cabotegravir (CAB) and rilpivirine (RPV) is the first long-acting injectable antiretroviral therapy (ART) option approved for virologically suppressed adults with HIV-1. In addition, long-acting CAB is a promising agent for HIV preexposure prophylaxis (PrEP). This review...

Cite
Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS. 2022;17(1):22-31doi: 10.1097/COH.0000000000000708.
Bares, S. H., & Scarsi, K. K. (2022). A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Current opinion in HIV and AIDS, 17(1), 22-31. https://doi.org/10.1097/COH.0000000000000708
Bares, Sara H, and Scarsi, Kimberly K. "A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV." Current opinion in HIV and AIDS vol. 17,1 (2022): 22-31. doi: https://doi.org/10.1097/COH.0000000000000708
Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS. 2022 Jan 01;17(1):22-31. doi: 10.1097/COH.0000000000000708. PMID: 34871188; PMCID: PMC8694245.
Copy Download .nbib Format: NLM
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.

Journal of the International AIDS Society

Scarsi K, Lamorde M, Darin K, Penchala SD, Else L, Nakalema S, Byakika-Kibwika P, Khoo S, Cohn S, Merry C, Back D.
PMID: 25393993
J Int AIDS Soc. 2014 Nov 02;17(4):19484. doi: 10.7448/IAS.17.4.19484. eCollection 2014.

INTRODUCTION: Sub-dermal hormone implants, such as levonorgestrel (LNG), are a safe and desirable form of long-acting contraception, but their use among HIV-positive women on antiretroviral therapy (ART) may be compromised given the potential for a cytochrome P450 3A-mediated drug-drug...

Cite
Scarsi K, Lamorde M, Darin K, et al. Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc. 2014;17(4):19484doi: 10.7448/IAS.17.4.19484.
Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., Byakika-Kibwika, P., Khoo, S., Cohn, S., Merry, C., & Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. Journal of the International AIDS Society, 17(4), 19484. https://doi.org/10.7448/IAS.17.4.19484
Scarsi, Kimberly, et al. "Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant." Journal of the International AIDS Society vol. 17,4 (2014): 19484. doi: https://doi.org/10.7448/IAS.17.4.19484
Scarsi K, Lamorde M, Darin K, Penchala SD, Else L, Nakalema S, Byakika-Kibwika P, Khoo S, Cohn S, Merry C, Back D. Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc. 2014 Nov 02;17(4):19484. doi: 10.7448/IAS.17.4.19484. eCollection 2014. PMID: 25393993; PMCID: PMC4224805.
Copy Download .nbib Format: NLM
An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia.

Muscle & nerve

Gemelli C, Traverso M, Trevisan L, Fabbri S, Scarsi E, Carlini B, Prada V, Mongini T, Ruggiero L, Patrone S, Gallone S, Iodice R, Pisciotta L, Zara F, Origone P, Rota E, Minetti C, Bruno C, Schenone A, Mandich P, Fiorillo C, Grandis M.
PMID: 34687219
Muscle Nerve. 2021 Oct 23; doi: 10.1002/mus.27448. Epub 2021 Oct 23.

INTRODUCTION/AIMS: Currently, there are no straightforward guidelines for the clinical and diagnostic management of hyperCKemia, a frequent and nonspecific presentation in muscle diseases. Therefore, we aimed to describe our diagnostic workflow for evaluating patients with this condition.METHODS: We selected...

Cite
Gemelli C, Traverso M, Trevisan L, et al. An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia. Muscle Nerve. 2021;doi: 10.1002/mus.27448.
Gemelli, C., Traverso, M., Trevisan, L., Fabbri, S., Scarsi, E., Carlini, B., Prada, V., Mongini, T., Ruggiero, L., Patrone, S., Gallone, S., Iodice, R., Pisciotta, L., Zara, F., Origone, P., Rota, E., Minetti, C., Bruno, C., Schenone, A., Mandich, P., Fiorillo, C., & Grandis, M. (2021). An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia. Muscle & nerve, . https://doi.org/10.1002/mus.27448
Gemelli, Chiara, et al. "An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia." Muscle & nerve vol. (2021). doi: https://doi.org/10.1002/mus.27448
Gemelli C, Traverso M, Trevisan L, Fabbri S, Scarsi E, Carlini B, Prada V, Mongini T, Ruggiero L, Patrone S, Gallone S, Iodice R, Pisciotta L, Zara F, Origone P, Rota E, Minetti C, Bruno C, Schenone A, Mandich P, Fiorillo C, Grandis M. An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia. Muscle Nerve. 2021 Oct 23; doi: 10.1002/mus.27448. Epub 2021 Oct 23. PMID: 34687219.
Copy Download .nbib Format: NLM
Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns.

Journal of materials chemistry. B

Lucío MI, Opri R, Pinto M, Scarsi A, Fierro JLG, Meneghetti M, Fracasso G, Prato M, Vázquez E, Herrero MA.
PMID: 32264275
J Mater Chem B. 2017 Nov 28;5(44):8821-8832. doi: 10.1039/c7tb02464a. Epub 2017 Nov 01.

The ability of carbon nanohorns (CNHs) to cross biological barriers makes them potential carriers for delivery purposes. In this work, we report the design of a new selective antibody-drug nanosystem based on CNHs for the treatment of prostate cancer...

Cite
Lucío MI, Opri R, Pinto M, et al. Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns. J Mater Chem B. 2017;5(44):8821-8832doi: 10.1039/c7tb02464a.
Lucío, M. I., Opri, R., Pinto, M., Scarsi, A., Fierro, J. L. G., Meneghetti, M., Fracasso, G., Prato, M., Vázquez, E., & Herrero, M. A. (2017). Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns. Journal of materials chemistry. B, 5(44), 8821-8832. https://doi.org/10.1039/c7tb02464a
Lucío, María Isabel, et al. "Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns." Journal of materials chemistry. B vol. 5,44 (2017): 8821-8832. doi: https://doi.org/10.1039/c7tb02464a
Lucío MI, Opri R, Pinto M, Scarsi A, Fierro JLG, Meneghetti M, Fracasso G, Prato M, Vázquez E, Herrero MA. Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns. J Mater Chem B. 2017 Nov 28;5(44):8821-8832. doi: 10.1039/c7tb02464a. Epub 2017 Nov 01. PMID: 32264275.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries